Get started
Author

Michael F Murphy

Observed names: M. Murphy, MICHAEL F. MURPHY, Michael F. Murphy, Michael F. Murphy M.D., Ph.D., Michael Murphy
ORCID: 0000-0002-6160-2756
Observed ORCID: 0000-0002-6160-2756
OpenAlex ID: A5101696757
Sex differences in the psychopharmacological treatment of depression
2016 · John J. Sramek, Michael F. Murphy, et al. · Dialogues in Clinical Neuroscience · 345
Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.
2011 · Henry J Riordan, Paola Antonini, et al. · Europe PMC (PubMed Central) · 97
NM101 Phase III Study of NE3107 in Alzheimer’s Disease: rationale, Design and Therapeutic Modulation of Neuroinflammation and Insulin Resistance
2021 · Christopher L Reading, Clarence N Ahlem, et al. · Neurodegenerative Disease Management · 85
A Double-Blind Randomized Placebo-Controlled Pilot Study of Neuropsychiatric Adverse Events in Abstinent Smokers Treated with Varenicline or Placebo
2011 · Dahlia Garza, Michael Murphy, et al. · Biological Psychiatry · 51
Sex and Gender in Adverse Drug Events, Addiction, and Placebo
2012 · Flavia Franconi, Ilaria Campesi, et al. · Handbook of experimental pharmacology · 50
Evaluation of HP 029 (Velnacrine Maleate) in Alzheimer's Diseasea
1991 · MICHAEL F. MURPHY, STEPHEN T. HARDIMAN, et al. · Annals of the New York Academy of Sciences · 49
Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophrenia
2013 · Michael F. Egan, Xin Zhao, et al. · Human Psychopharmacology Clinical and Experimental · 42
Clinical Safety, Tolerance, and Plasma Levels of the Oral Anticholinesterase 1,2,3,4‐Tetrahydro‐9‐aminoacridin‐1‐oL‐maleate (HP 029) in Alzheimer's Disease: Preliminary Findings
1990 · Neal R. Cutler, Michael F. Murphy, et al. · The Journal of Clinical Pharmacology · 41
Tolerability of ORM‐12741 and effects on episodic memory in patients with Alzheimer's disease
2016 · Juha O. Rinne, Keith Wesnes, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 29
PDF
Efficacy and Safety of Lesopitron in Outpatients with Generalized Anxiety Disorder
2000 · Anna Fresquet, Mariano Sust, et al. · Annals of Pharmacotherapy · 26
Demonstrating Value for Biosimilars: A Conceptual Framework.
2015 · Sotiris Rompas, Thomas Goss, et al. · PubMed · 22
Implications of the Study Population in the Early Evaluation of Anticholinesterase Inhibitors for Alzheimer's Disease
1992 · Neal R. Cutler, John J. Sramek, et al. · Annals of Pharmacotherapy · 20
An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations
2009 · Anastasia Ivanova, Michael Murphy · Journal of Biopharmaceutical Statistics · 16
Critical Pathways to Success in CNS Drug Development
2010 · Neal R. Cutler, John J. Sramek, et al. · Wiley eBooks · 13
Effect of Six Months of Treatment with V0191 in Patients with Suspected Prodromal Alzheimer's Disease
2012 · Bruno Dubois, Mohammed Zaim, et al. · Journal of Alzheimer s Disease · 10
Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial
2017 · John Sramek, Antony Loebel, et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 9
PDF
Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer's disease: A randomized, double-blind, proof-of-concept study
2013 · J.O. Rinne, K. Wesnes, et al. · Journal of the Neurological Sciences · 9
Phase 1 Clinical Trials of Small Molecules: Evolution and State of the Art
2021 · John J. Sramek, Michael F. Murphy, et al. · Reviews on Recent Clinical Trials · 7
Toward an integrated discovery and development program in Alzheimer's disease: The amyloid hypothesis
1994 · Barry D. Greenberg, Michael F. Murphy · Neurobiology of Aging · 7
Alzheimer's Patients Should Be Included in Phase I Clinical Trials To Evaluate Compounds for Alzheimer's Disease
1992 · Neal R. Cutler, John J. Sramek, et al. · Journal of Geriatric Psychiatry and Neurology · 7
Pleocytosis in cerebrospinal fluid following multiple lumbar punctures in healthy volunteers
2015 · George Atiee, John Sramek, et al. · Journal of the Neurological Sciences · 5
Adverse events in placebo-treated patients with generalized anxiety disorder
1997 · John J. Sramek, Edyta J. Frackiewicz, et al. · Depression and Anxiety · 5
PDF
Clinical trials with velnacrine: (PROPP) The physician reference of predicted probabilities-A statistical model for the estimation of hepatotoxicity risk with velnacrine maleate
2009 · S. Hardiman, K. Miller, et al. · Acta Neurologica Scandinavica · 4
Pharmacogenomics and drug development.
2010 · Michael F Murphy · Europe PMC (PubMed Central) · 2
PW01-224 - Neuropsychiatric Symptoms In Smokers Quitting With Varenicline Or Placebo: A Double-Blind, Randomized, Controlled Pilot Study
2010 · D. Garza, M. Murphy, et al. · European Psychiatry · 2
Works count: 42
Citation count: 957
H-index: 13
I10-index: 15
Year
Topic
Type